A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

RecruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

March 1, 2024

Conditions
Respiratory Tuberculosis
Interventions
DRUG

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Trial Locations (13)

152284

COMPLETED

Yaroslavl regional tuberculosis clinic, Yaroslavl

187550

COMPLETED

Leningrad Oblast Tuberculosis Hospital in Tikhvin, Tikhvin

188560

COMPLETED

Leningrad Oblast Tuberculosis Clinic, Slantsy

196142

NOT_YET_RECRUITING

City tuberculosis clinic, Saint Petersburg

390046

COMPLETED

Ryazan Oblast Tuberculosis Clinic, Ryazan

394070

COMPLETED

N. S. Pokhvisneva Voronezh Oblast Clinical Tuberculosis Dispensary, Voronezh

400005

RECRUITING

Volgograd Oblast Tuberculosis Clinic, Volgograd

414004

RECRUITING

Astrakhan Oblast Tuberculosis Clinic, Astrakhan

420075

RECRUITING

Republican Tuberculosis Clinic, Kazan'

428015

RECRUITING

Tuberculosis Clinic of the Chuvash Republic, Cheboksary

450080

COMPLETED

Tuberculosis Clinic of the Republic of Bashkortostan, Ufa

614990

RECRUITING

Clinical Phthisiopulmonological Medical Center, Perm

620142

COMPLETED

Sverdlovsk Oblast Clinical Medical Center of Phthisiopulmonology and Infectious Diseases, Yekaterinburg

All Listed Sponsors
lead

SPP Pharmaclon Ltd.

INDUSTRY